High-grade gliomas (HGG) represent about 15% of all pediatric brain tumors, with a dismal prognosis and survival rates ranging from 15 to 35%. Approximately 10-12% of pediatric HGGs (pHGG) occur in children younger than five years of age at diagnosis, specifically infants (iHGG), with an unexpected overall survival rate (OS) in 60-70% of cases. In the literature, iHGGs include a large variety of heterogeneous lesions with different molecular profiles that likely explain their different outcomes. We report our single-institution experience of iHGG including 11 children under five years of age with newly diagnosed HGG between 2011 and 2021. All patients received surgery and adjuvant chemotherapy; only two patients received radiotherapy because their age at diagnosis was more than four years-old. Molecular investigations, including next generation sequencing (NGS) and DNA methylation, detected three NTRK-fusions, one ROS1-fusions, one MN1-rearrangement, and two PATZ1-fusions. According to the molecular results, when chemotherapy failed to control the disease, two patients benefited from target therapy with a NTRK-Inhibitor larotrectinib, achieving a complete remission and a very good partial response, respectively, and no severe side-effects. In conclusion, molecular investigations play a fundamental role in the diagnostic work-up and also in the therapeutic decision. Their routine use in clinical practice could help to replace highly toxic chemotherapy regimens with a target therapy that has moderate adverse effects, even in long-term follow-up.

Molecular landscape in infant high-grade gliomas: a single center experience / Di Ruscio, Valentina; Carai, Andrea; Del Baldo, Giada; Vinci, Maria; Cacchione, Antonella; Miele, Evelina; Rossi, Sabrina; Antonelli, Manila; Barresi, Sabina; Caulo, Massimo; Colafati, Giovanna Stefania; Mastronuzzi, Angela. - In: DIAGNOSTICS. - ISSN 2075-4418. - 12:2(2022). [10.3390/diagnostics12020372]

Molecular landscape in infant high-grade gliomas: a single center experience

Di Ruscio, Valentina
Primo
;
Del Baldo, Giada;Cacchione, Antonella;Miele, Evelina;Rossi, Sabrina;Antonelli, Manila;Mastronuzzi, Angela
Ultimo
2022

Abstract

High-grade gliomas (HGG) represent about 15% of all pediatric brain tumors, with a dismal prognosis and survival rates ranging from 15 to 35%. Approximately 10-12% of pediatric HGGs (pHGG) occur in children younger than five years of age at diagnosis, specifically infants (iHGG), with an unexpected overall survival rate (OS) in 60-70% of cases. In the literature, iHGGs include a large variety of heterogeneous lesions with different molecular profiles that likely explain their different outcomes. We report our single-institution experience of iHGG including 11 children under five years of age with newly diagnosed HGG between 2011 and 2021. All patients received surgery and adjuvant chemotherapy; only two patients received radiotherapy because their age at diagnosis was more than four years-old. Molecular investigations, including next generation sequencing (NGS) and DNA methylation, detected three NTRK-fusions, one ROS1-fusions, one MN1-rearrangement, and two PATZ1-fusions. According to the molecular results, when chemotherapy failed to control the disease, two patients benefited from target therapy with a NTRK-Inhibitor larotrectinib, achieving a complete remission and a very good partial response, respectively, and no severe side-effects. In conclusion, molecular investigations play a fundamental role in the diagnostic work-up and also in the therapeutic decision. Their routine use in clinical practice could help to replace highly toxic chemotherapy regimens with a target therapy that has moderate adverse effects, even in long-term follow-up.
2022
infants; larotrectinib; molecular profile; oncogenic fusions; pediatric high-grade gliomas; target therapy
01 Pubblicazione su rivista::01a Articolo in rivista
Molecular landscape in infant high-grade gliomas: a single center experience / Di Ruscio, Valentina; Carai, Andrea; Del Baldo, Giada; Vinci, Maria; Cacchione, Antonella; Miele, Evelina; Rossi, Sabrina; Antonelli, Manila; Barresi, Sabina; Caulo, Massimo; Colafati, Giovanna Stefania; Mastronuzzi, Angela. - In: DIAGNOSTICS. - ISSN 2075-4418. - 12:2(2022). [10.3390/diagnostics12020372]
File allegati a questo prodotto
File Dimensione Formato  
Di-Ruscio_Molecular_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 4.94 MB
Formato Adobe PDF
4.94 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1672811
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact